, proposition des différents schémas thérapeutiques pour le Génotype 5 et 6 (D'après l'AFEF 05/2015) Bibliographie : 1. Lindenbach BD. Virion Assembly and Release, vol.15, pp.199-218, 2013.
,
, Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique, Hepatol Res Off J Jpn Soc Hepatol. juill, vol.20, issue.3, pp.335-382, 2001.
The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum, J Virol. avr, vol.73, issue.4, pp.2641-2650, 1999. ,
Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle, FEBS J. sept, vol.274, issue.18, pp.4705-4723, 2007. ,
Unravelling hepatitis C virus replication from genome to function, Nature. 18 août, vol.436, issue.7053, pp.933-941, 2005. ,
Processing and Functions of Hepatitis C Virus Proteins, Intervirology, vol.42, issue.2--3, pp.145-52, 1999. ,
Structural biology of hepatitis C virus, Hepatol Baltim Md. janv, vol.39, issue.1, pp.5-19, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00313693
Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes, J Gen Virol. févr, vol.88, pp.458-69, 2007. ,
The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. janv, vol.535, issue.1--3, pp.34-42, 2003. ,
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype--specific sequences, Proc Natl Acad Sci, vol.100, issue.20, pp.11646-51, 2003. ,
A Concerted Action of Hepatitis C Virus P7 and Nonstructural Protein 2 Regulates Core Localization at the Endoplasmic Reticulum and Virus Assembly, PLoS Pathog. 21 juill, vol.7, issue.7, p.1002144, 2011. ,
The subcellular localization of the hepatitis C virus non--structural protein NS2 is regulated by an ion channel--independent function of the p7 protein, J Gen Virol. avr, vol.92, pp.819-849, 2011. ,
Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus, J Virol. août, vol.67, issue.8, pp.4665-75, 1993. ,
,
, Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication, J Biol Chem. 19 août, vol.280, issue.33, pp.29604-29615, 2005.
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus, J Virol. août, vol.81, issue.16, pp.8374-83, 2007. ,
Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1--E2 Glycoprotein and NS3--NS4A Enzyme Complexes, J Virol. sept, vol.83, issue.17, pp.8379-95, 2009. ,
Genetic and functional characterization of the N--terminal region of the hepatitis C virus NS2 protein, J Virol. avr, vol.87, issue.8, pp.4130-4175, 2013. ,
Nonstructural protein 3--4A: the Swiss army knife of hepatitis C virus, J Viral Hepat. mai, vol.18, issue.5, pp.305-320, 2011. ,
An amino--terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A, J Virol. mars, vol.69, issue.3, pp.1769-77, 1995. ,
Subcellular localization, stability, and trans--cleavage competence of the hepatitis C virus NS3--NS4A complex expressed in tetracycline--regulated cell lines, J Virol. mars, vol.74, issue.5, pp.2293-304, 2000. ,
Topology of the membrane--associated hepatitis C virus protein NS4B, J Virol. mai, vol.77, issue.9, pp.5428-5466, 2003. ,
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex, J Virol. juin, vol.76, issue.12, pp.5974-84, 2002. ,
An amino-terminal amphipathic alpha--helix mediates membrane association of the hepatitis C virus nonstructural protein 5A, J Biol Chem. 8 mars, vol.277, issue.10, pp.8130-8139, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-00313705
The NS5A protein of hepatitis C virus is a zinc metalloprotein, J Biol Chem, vol.279, issue.47, pp.48576-87, 2004. ,
Structure of the zinc--binding domain of an essential component of the hepatitis C virus replicase, Nature. 19 mai, vol.435, issue.7040, pp.374-383, 2005. ,
The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release, J Gen Virol. 1 mai, vol.94, pp.1009-1027, 2013. ,
Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly, PLoS Pathog. 28 mars, vol.4, issue.3, p.1000035, 2008. ,
Efficient initiation of HCV RNA replication in cell culture, Science. 8 déc, vol.290, issue.5498, pp.1972-1976, 2000. ,
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication, J Virol. déc, vol.76, issue.24, pp.13001-13015, 2002. ,
DOI : 10.1128/jvi.76.24.13001-13014.2002
URL : https://jvi.asm.org/content/76/24/13001.full.pdf
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture, J Virol. mars, vol.77, issue.5, pp.3181-90, 2003. ,
Viral and cellular determinants of hepatitis C virus RNA replication in cell culture, J Virol. mars, vol.77, issue.5, pp.3007-3026, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00313699
Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain, J Virol. mars, vol.79, issue.5, pp.3187-94, 2005. ,
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication, Proc Natl Acad Sci U S A. 31 août, vol.101, issue.35, pp.13038-13081, 2004. ,
DOI : 10.1073/pnas.0405152101
URL : http://www.pnas.org/content/101/35/13038.full.pdf
Reduction of Hepatitis C Virus NS5A Hyperphosphorylation by Selective Inhibition of Cellular Kinases Activates Viral RNA Replication in Cell Culture, J Virol. déc, vol.78, issue.23, pp.13306-13320, 2004. ,
Membrane association of the RNA--dependent RNA polymerase is essential for hepatitis C virus RNA replication, J Virol. déc, vol.78, issue.23, pp.13278-84, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00313684
, Variabilité génétique du virus de l'hépatite C : implications cliniques, vol.29
,
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon--alpha therapy, Science, vol.282, issue.5386, pp.103-110, 1998. ,
Hépatites virales B et C [Internet ,
,
Les infection par le virus de l'hépatite C dans le monde : importance en santé publique, modes de transmission et perspectives, Virologie. 1 juill, vol.7, issue.3, pp.177-91, 2003. ,
Global Distribution and Prevalence of Hepatitis C Virus Genotypes, Hepatol Baltim Md. janv, vol.61, issue.1, pp.77-87, 2015. ,
The hepatitis C virus, 2002. ,
Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies, J Hepatol. 1 mars, vol.54, issue.3, pp.566-76, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00701487
,
, Hepatitis C Virus Entry Depends on Clathrin--Mediated Endocytosis, J Virol. juill, vol.80, issue.14, pp.6964-72, 2006.
Early steps of the hepatitis C virus life cycle, Cell Microbiol. 1 avr, vol.10, issue.4, pp.821-828, 2008. ,
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate, J Biol Chem, vol.278, issue.42, pp.41003-41015, 2003. ,
How C--type lectins detect pathogens, Cell Microbiol. avr, vol.7, issue.4, pp.481-489, 2005. ,
The low--density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus, J Hepatol. mars, vol.46, issue.3, pp.411-420, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00374413
Entrée cellulaire du virus de l'hépatite C, Virologie. 1 mai, vol.10, issue.3, pp.179-91, 2006. ,
Binding of hepatitis C virus to CD81. Science, vol.282, pp.938-979, 1998. ,
Claudin--1 is a hepatitis C virus co--receptor required for a late step in entry, Nature. 12 avr, vol.446, issue.7137, pp.801-806, 2007. ,
The Tight Junction--Associated Protein Occludin Is Required for a Postbinding Step in Hepatitis C Virus Entry and Infection, J Virol. août, vol.83, issue.16, pp.8012-8032, 2009. ,
How viruses enter animal cells, Science. 9 avr, vol.304, issue.5668, pp.237-279, 2004. ,
Internal ribosome entry site within hepatitis C virus RNA, J Virol. mars, vol.66, issue.3, pp.1476-83, 1992. ,
55. ledinghen victorde. Histoire naturelle de l'infection par le virus de l'hépatite C. /data/revues/03998320/00260HS2/9, Clin Mol Hepatol. mars, vol.19, issue.1, pp.17-25, 2008. ,
URL : https://hal.archives-ouvertes.fr/in2p3-00023812
,
Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C, 2014. ,
, Histoire naturelle de l'infection par le virus de l'hépatite C
, Disponible sur, 2015.
Histoire naturelle et diagnostic de l'hépatite C, J Pharm Clin. 1 janv, vol.25, issue.1, pp.49-56, 2006. ,
HAS. conditions de réalisation des tests rapides d'orientation diagnostique de l'infection à virus de l'immunodéficience humaine (VIH 1 et 2) et de l'infection à virus de l'hépatite C (VHC) en milieu médicosocial et associatif, Les manifestations extra--hépatiques au cours de l'infection par le virus de l'hépatite C [Internet]. Disponible sur ,
, Gastro Oncol Dig. 1 mai, vol.16, issue.3, pp.219-239, 2009.
Place de la ponction--biopsie hépatique dans la prise en charge de l'hépatite chronique C. /data/revues/03998320/00260HS2/168, vol.29, 2008. ,
,
Évaluation non--invasive de la fibrose hépatique au cours de l'hépatite C, Gastroentérologie Clin Biol. mars, vol.32, issue.3, pp.90-95, 2008. ,
évaluation de la fibrose hépatique, Gastro Oncol Dig. 1 juill, vol.12, issue.4, pp.251-260, 2005. ,
,
, , p.25, 2014.
,
Prévalence des hépatites B et C en france en, InVS, 2004. ,
Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States, Clin Infect Dis. 15 juill, vol.55, issue.1, pp.10-15, 2012. ,
Transmission de l'hépatite C ,
,
, Pike, vol.8600
,
Hépatite C et transplantation hépatique ,
, DOROSZ guide pratique des médicaments 2015. 34ème édition. Pages 904, p.905, 2015.
Interférons : des mécanismes d'action aux applications cliniques en hépatologie. Médecine Thérapeutique. 30 juin, vol.4, pp.323-354, 1998. ,
, DOROSZ guide pratique des médicaments 2015. 34ème édition. Pages 909, p.911
, , p.145
,
,
,
,
Nouveaux antiviraux actifs contre le virus de l'hépatite C ,
,
,
,
,
, Résumé des caractéristiques du produit de HARVONI.Annexe, vol.1
,
,
, Résumé des caractéristiques du produit de EXVIERA. Annexe, vol.1
, Pike, vol.8600
,
, Pike, vol.8600
,
O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1--infected patients with child-pugh class B cirrhosis (C--salt part A), J Hepatol. 1 avr, vol.62, pp.193-197, 2015. ,
A Phase 3, randomised, open--label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment--naïve and--experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST--1 [Internet]. vienne, pp.22-26, 2015. ,
LO3 : Safety and efficacy of the combination daclatasvir--sofosbuvir in HCV genotype 1-mono--infected patients from the french observational cohort ANRS CO22 hepather*, J Hepatol. avr, vol.62, pp.258-267, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162711
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection, N Engl J Med. 15 mai, vol.370, issue.20, pp.1889-98, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01690189
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection, N Engl J Med. 17 avr, vol.370, issue.16, pp.1483-93, 2014. ,
Treatment of HCV with ABT--450/r-Ombitasvir and Dasabuvir with Ribavirin, N Engl J Med. 24 avr, vol.370, issue.17, pp.1594-603, 2014. ,
O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir--based regimens with ledipasvir/sofosbuvir for 24 weeks, J Hepatol. 1 avr, vol.62, p.192, 2015. ,
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK--5172) and elbasvir (MK--8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C--WORTHY): a randomised, open--label phase 2 trial, Lancet Lond Engl. 21 mars, vol.385, issue.9973, pp.1075-86, 2015. ,
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, N Engl J Med. 16 mai, vol.368, issue.20, pp.1878-87, 2013. ,
, Safety and Efficacy of Sofosbuvir--Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort
,
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, N Engl J Med. 16 janv, vol.370, issue.3, pp.211-232, 2014. ,
All--oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY--3 phase III study, Hepatol Baltim Md. avr, vol.61, issue.4, pp.1127-1162, 2015. ,
LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program, J Hepatol, vol.62, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162768
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon--Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment--Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection, Gastroenterology. nov, vol.149, issue.6, pp.1462-70, 2015. ,
LP28 : Efficacy of the oral sofosbuvir--based combinations in HCV genotype 4--mono--infected patients from the french observational cohort anrs CO22 hepather, J Hepatol. 1 avr, vol.62, p.278, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01162770
,
,
,
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment--naive and treatment--experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL--I): a randomised, open--label trial, The Lancet. juin, vol.385, issue.9986, pp.2502-2511, 2015. ,
Grazoprevir-Elbasvir Combination Therapy for Treatment--Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial, Ann Intern Med. 7 juill, vol.163, issue.1, pp.1-13, 2015. ,
Efficacy and safety of grazoprevir (MK--5172) and elbasvir (MK--8742) in patients with hepatitis C virus and HIV co--infection (C--EDGE CO--INFECTION): a non--randomised, open--label trial, Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono--and HCV/HIV Co-infected Patients, vol.2, pp.319-346, 2015. ,
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial, JAMA. 28 août, vol.310, issue.8, pp.804-815, 2013. ,
Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale--Up in Persons Who Inject Drugs in Metropolitan Chicago, PLoS ONE. 21 août, vol.10, issue.8, p.135901, 2015. ,
Cours d'université de 2eme année de médecine Rennes 1 « Sémiologie biologique hépatique, 2009. ,
, Traitement de l'hépatite C après transplantation hépatique. /data/revues/03998320/00260HS2/231, vol.29
,
, Impact de la cinétique virale au cours du traitement de la récidive du VHC après TH (étude ANRS CO23 CUPILT), 2015.
résultats d'un programme d'accès aux Etats--unis [Internet]. AASLD, 2015. ,
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection, N Engl J Med. 31 déc, vol.373, issue.27, pp.2599-607, 2015. ,
, combinaison d'antiviraux directs de nouvelle génération: ABT--493 et ABT--530 : 97%--100% de RVS12, pour les G1, non--cirrhotiques, naïfs ou répondeurs nuls à PEG RBV (SURVEYOR--1), 2015.
Amélioration de la maladie hépatique après traitement par sofosbuvir et daclatasvir plus ribavirine chez des patients ayant une cirrhose sévère ,
, AASLD, 2015.
Nouveaux antiviraux directs : quel impact sur les listes d'attente de TH ?, AASLD, 2015. ,